Priming increases the anti-tumor effect and therapeutic window of (177)Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1

BACKGROUND: (177)Lu-[DOTA(0), Tyr(3)]-octreotate ((177)Lu-octreotate) is used for treatment of patients with somatostatin receptor (SSTR) expressing neuroendocrine tumors. However, complete tumor remission is rarely seen, and optimization of treatment protocols is needed. In vitro studies have shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalmo, Johanna, Spetz, Johan, Montelius, Mikael, Langen, Britta, Arvidsson, Yvonne, Johansson, Henrik, Parris, Toshima Z., Helou, Khalil, Wängberg, Bo, Nilsson, Ola, Ljungberg, Maria, Forssell-Aronsson, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241264/
https://www.ncbi.nlm.nih.gov/pubmed/28097640
http://dx.doi.org/10.1186/s13550-016-0247-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241264/
https://www.ncbi.nlm.nih.gov/pubmed/28097640
http://dx.doi.org/10.1186/s13550-016-0247-y

Ejemplares similares